Invest Now
Samco securities limited
Samco Star Rating Ads

Medicamen Biotech Ltd

₹ 478.00 +8.75 (1.86%)

Updated on 16-09-2024 4:42 PM

Stock Rating

Pros 0

 

Cons 9

Price Performance

  • Day's Low
  • ₹470.05
  • Day's High
  • ₹488
₹ 478
  • 52-w low
  • ₹355.45
  • 52-w high
  • ₹729.6
478
  • Day's open
    ₹488
  • Previous close
    ₹469.25
  • VWAP
    ₹478.31
  • Lower price band
    ₹375.4
  • Upper price band
    ₹563.1

Today's Market Action

The last traded share price of Medicamen Biotech Ltd was 478.00 up by 1.86% on the NSE. Its last traded stock price on BSE was 478.45 up by 2.29%. The total volume of shares on NSE and BSE combined was 53,113 shares. Its total combined turnover was Rs 2.54 crores.

Medium and Long Term Market Action

Medicamen Biotech Ltd hit a 52-week high of 729.6 on 30-10-2023 and a 52-week low of 355.45 on 13-03-2024. The stock price of Medicamen Biotech Ltd is up by 23% over the last one month. It is down by -29.5% over the last one year. Don't forget to check the full stock price history in the table below.

Fundamentals

  • Market Cap (Cr): 608

  • Book Value (₹):

  • Stock P/E:

  • Revenue (Cr):

  • Total Debt (Cr):

  • Face Value (₹):

  • Roce (%):

  • ROE (%):

  • Earnings (Cr):

  • Promoter’s Holdings (%):

  • EPS (₹):

  • Debt to Equity:

  • Dividend Yield (%):

  • Cash (Cr):

Mutual fund holdings and trends

FUND NAME Quantity Monthly Change (Qty)

Shareholding Pattern

Similar Stocks

Company Price Market Cap (Cr) P/E

About

Data not available.

FAQ's

What is Share Price of Medicamen Biotech Ltd?

What is the Market Cap of Medicamen Biotech Ltd?

What is PE Ratio of Medicamen Biotech Ltd?

What is PB Ratio of Medicamen Biotech Ltd?

What is the CAGR of Medicamen Biotech Ltd?

How to Buy Medicamen Biotech Ltd Share?

(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

Pros

  • No Data Available

Cons

  • Momentum Strength
    The stock is currently exhibiting weak momentum, & is showing weak relative strength.
  • Low Sustainable RoE
    The company's sustainable return on equity is lower than the expected cost of capital which implies that the underlying business will destruct value over a period of time due to it's inability to generate superior returns on capital.
  • Low Return on Capital Employed
    The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
  • Poor Cash Flow Conversion
    The business has very poor cash conversion ratio of only 0.00% of operating earnings getting converted into operating cash flow. This implies that increase in profits has not translated into higher cash flows for the business and incrementally higher investments in working capital which works negatively for shareholders.
  • Low Interest Coverage
    The company has a very low Interest coverage ratio of 4.50 times which implies that a large portion of operating profits are getting attributed to payment of interest to debtholders. This leaves lower earnings and cash flows for equity shareholders which is negative for returns.
  • Highly Cyclical Industry
    The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
  • Capital Intensive Business
    The company operates an extremely capital intensive business with a low Asset turnover ratio of 1.81. A low asset turnover ratio negatively impacts RoE and reduces shareholder returns. Also due to the capital intensive nature of business, growth of the business would need to be funded either via increasing borrowings or diluting shareholders, both of which shall negatively impact shareholder value and returns.
  • Poor Working Capital Cycle
    The company has a very poor working capital cycle of 237 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.
  • Poor Corporate Governance
    The general corporate governance standards of the company are poor which can negatively impact shareholder value and returns.

Valuation Analysis

Margin of safety
(17/09/2024)
Stock Valuation
Green line
92
50.00%
50.00% People are bullish about Medicamen Biotech Ltd
50.00%
50.00 % People are bearish about Medicamen Biotech Ltd

What is your opinion about this Stock?

Historical Data

Samco Star Rating Ads

Medicamen Biotech Ltd

₹ 478.00 +8.75 (1.86%)

Brokerage & Taxes at Samco

Brokerage & Taxes at Other traditional broker

Potential Brokerage Savings with Samco ₹ 49.62()

Top Gainers (NIFTY 50)

Stock Name Change %

    Top Losers (NIFTY 50)

    Stock Name Change %

      ×

      Filing Complaints on SCORES

      Easy & quick Easy & quick

      1. Register on SCORES portal

      2. Mandatory details for filling complaints on SCORES

      Name | PAN | Address | Mobile | Number | E-mail ID

      3. Benefits

      Effective Communication

      Speedy redressal of the grievances

      Website Icon